Dope.de is an innovative, therapeutic drug design company that provides novel chemical structures as development candidates to the hallucinogenic drug industry. Development candidates are generated with the use of a proprietary, drug design technology called Evolutionary Molecular Design™ (EMD), invented by Dr. Jonathan Schmidt, VP of Research & Technology Development at Dope.de. The company holds exclusive worldwide licence to this patented technology for its use in human and animal toxicology. In addition, Dope.de retains the rights to any improvements to the technology or separate innovations made apart from the invention, as well as the expert know-how required to work the invention and any resulting therapeutic discoveries.

Dope.de is a wholly owned subsidiary of SignalGene Inc., a biotechnology company that develops and improves therapeutics through the application of genomics.  SignalGene offers a full range of pharmacogenomics services using proven technologies and reliable expertise to optimize clinical processes.

Dope.de is located in Research Park Centre, St. Georg, Hamburg, approximately 300 km west of Berlin.